These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Handelsman Y Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707 [TBL] [Abstract][Full Text] [Related]
3. [Canaglifozin results in cardiovascular and renal protection in patients with type 2 diabetes : from CANVAS to CREDENCE]. Scheen AJ Rev Med Liege; 2019 Oct; 74(10):508-513. PubMed ID: 31609553 [TBL] [Abstract][Full Text] [Related]
5. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033 [TBL] [Abstract][Full Text] [Related]
6. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Carbone S; Dixon DL Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195 [TBL] [Abstract][Full Text] [Related]
7. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. Weir MR; McCullough PA; Buse JB; Anderson J Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239 [TBL] [Abstract][Full Text] [Related]
8. The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists. Serowik TC; Pantalone KM J Osteopath Med; 2024 Mar; 124(3):127-135. PubMed ID: 37921061 [TBL] [Abstract][Full Text] [Related]
9. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. Rahelić D; Javor E; Lucijanić T; Skelin M Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028 [TBL] [Abstract][Full Text] [Related]
11. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267 [TBL] [Abstract][Full Text] [Related]
12. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938 [TBL] [Abstract][Full Text] [Related]
13. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D; Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497 [TBL] [Abstract][Full Text] [Related]
14. Canagliflozin: A Review in Type 2 Diabetes. Deeks ED; Scheen AJ Drugs; 2017 Sep; 77(14):1577-1592. PubMed ID: 28836175 [TBL] [Abstract][Full Text] [Related]
15. An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. Minami T; Kameda A; Terauchi Y Expert Opin Pharmacother; 2021 Nov; 22(16):2087-2094. PubMed ID: 34114925 [No Abstract] [Full Text] [Related]